Open AccessOsimertinib and Capmatinib Combination Therapy to Overcome MET Y1003N-Mediated Resistance in EGFR-Mutant NSCLC: A Case Report
Author(s) -
M. Wilgucki,
Vincent Yeung,
Grace W.K. Ho,
Gabriela L. Bravo Montenegro,
Greg Jones,
Joshua E. Reuss,
Stephen V. Liu,
Chul Kim
Publication year - 2022
Publication title -
jto clinical and research reports
Language(s) - English
Resource type - Journals
ISSN - 2666-3643
DOI - 10.1016/j.jtocrr.2022.100396
Subject(s) - osimertinib , mutant , cancer research , medicine , mutation , oncology , acquired resistance , point mutation , epidermal growth factor receptor , biology , cancer , genetics , erlotinib , gene